Wave Tanzania is pulmonary hypertension specific, but the drug sales in China is limited, sample hospital patients with less than 7 million yuan annual sales shows that a large number of domestic not yet used the varieties. Born wave 2016 temple sellers love can tyrone take the initiative to reduce our price by 80%, after the price is about 10% increase in sales, though, but sales rose more than six times, indicating that prices can bring the huge market capacity. This price negotiation, which the country expects to reduce its price once again, even if the decline is less than 50 per cent, is clear for patients.
Before the new medical insurance directory recombinant coagulation factor Ⅷ, restructuring of clotting factor Ⅸ all entered the medical insurance directory, and the use range is open, belong to the same hemophilia drugs of recombinant coagulation factor Ⅶ directory has entered a negotiation. Restructuring Ⅶ a clotting factors applicable to use Ⅷ, Ⅸ factor antibody or inappropriate use of Ⅷ, Ⅸ factor. At present domestic sale of novo nordisk's only, the drug prophylaxis need long-term high prices and theory, it increase the burden of the patients, through the price negotiation is expected to significantly reduce the treatment cost, at the same time that more patients can bear the cost of the prevention and treatment of hemophilia.
Lanthanum carbonate and si vera are end-stage renal disease hyperphosphatemia main medicines, more than 1 million people at present Chinese patients with end-stage renal disease, end-stage renal disease patients generally require dialysis treatment, resulting in many dialysis patients can appear hyperphosphatemia, if blood phosphorus cannot effectively ruled out, can easily lead to patients with cardiovascular events and death. Given that calcium supplements may affect the calcium balance in the process of phosphorus removal, the current best treatment for hyperphosphatimia is lanthanum and svelum. Given the high cost of routine treatment for patients with end-stage nephropathy, reducing the cost of the treatment for high phosphatemia can help improve the quality of life for patients with end-stage kidney disease.
Anglo-American resistance
Price reduction will: yes
Youngson's anglo-french drug, tnf-alpha, is widely used in the drug, but this price negotiation is restricted to crohn's disease. Crohn's disease is an inflammatory bowel disease and is commonly referred to as a rare disease, but the disease is increasing in China. The treatment of crohn's disease is also limited, and tnf-alpha, which is included in the UK, is a more effective treatment. But still need to point out is, at present the, xidan resistance for crohn's disease accounts for only a small proportion of its clinical application, on the one hand, yeung sum or will be less willing to only a fraction for the market to change English, xidan price strategy, on the other hand, in the implementation level of drug bidding the net also different indications for the same product use different bidding price.
5 cardiovascular medications:
Domestic types of new drugs dominate
In the current disease of heart head blood-vessel is still the people under the condition of the primary cause of death, the negotiations directory five into western medicine of heart head blood-vessel, combined with traditional Chinese medicine with a total of nine varieties. The other varieties of the species that enter the catalogue are the domestic class of new drugs.
Euriklin, recombinant ureterase, digrel, alishatanate
A: yes, please
As living standards improve and working pressure increases, the incidence of cerebral infarction myocardial infarction and coronary syndrome rising, the guangdong temple yuri orlov franklin, tasly restructuring of urokinase and astrazeneca's for Greg los are mainly used for the treatment of the disease.
Yuri orlov kling extracted from human urine urine peptide enzyme, the drug by improving the brain blood flow perfusion and collateral circulation is used in the treatment of cerebral infarction, the drug listed more than a decade, the market continues to grow, 2016 samples of hospital sales of more than 60 million yuan, if enter the health care would extend the opportunity.
Recombinant urea is a precursor of the ureterase, which has powerful thrombolytic functions and recombinant drugs to better ensure purity and the source of the material. Drug pricing, however, significantly higher than that of urokinase and streptokinase health class a similar products, so the price into the health care products to help the follow-up of promotion, in addition to the drug and atenolol, enzyme, two or three generations of enzymes in the red at the contrast of thrombolytic drugs, more research is needed to support evidence.
Tigrello is the latest anti-platelet drug in the country, with a sales of 100 million yuan in just four years. Part concluded for Greg los in reducing the risk of adverse cardiovascular events and death, etc is superior to the current first-line drug clopidogrel, in addition to the drug without enzyme activation is not affected by gene polymorphism in the body. However, the cost of the treatment, which is far higher than that of clopidogrel, is preventing the majority of patients from taking the drug option, and by getting access to health care, they are expected to increase their chances of taking the drug.
Xinli tai temple, sand ester is of independent research and development of the domestic first statins, a new drug, the varieties listed make letter litai no longer rely solely on tai jia, but considering the most ARB drugs have entered the clinical health care, so the xinli company keen to alicante, sand ester negotiations listed in the catalog, refer to the prices of other ARB drugs, reduction should not be too big.
Reorganize the brain's sodium peptide
A: yes, please
Tibetan medicine is recombinant human brain natriuretic peptide in heart failure treatment, as a kind of new drugs to the drug has listed more than 12 years, 2016 annual report showed that the drug, annual sales reached 370 million yuan, but considering the basic not to enter the drug before the local supplementary medical insurance directory, so the varieties of Tibetan pharmacy for the big price cuts into the will of health care is not strong, I'm afraid.
Other areas
(eye, diabetes, psychosis)
Lebezumab, compaq, leularu, and escene
A: yes, please
In other areas, the biggest concern is two competing goods directly novartis's licensed and compaq heap yasuhiro miyata, resistance mechanism of two drugs similar to that of indications are basically the same. As one of the world's best-selling ophthalmological drugs, thunderball monoclonal antibodies have been strongly challenged in both foreign countries and at home. BaiXiPu o in the global market has more than licensed resistance, resistance and licensed in China although the share is ahead, but according to the PDB data, 2016 licensed a slight drop in sales resistance appeared, and compaq heap to maintain the 80% growth, the annual report of compaq heap, 2016 sales reached 2016 yuan. The high cost of treatment and almost can't through the reimbursement hindered the use of some patients, so licensed resistance and compaq heap has a greater willingness to cut into the health care before the licensed will take the initiative to reduce our price by 20%.
In the field of hypoglycemic, and DPP - all four drugs into health care, glp-1 drugs only beneficial lalu peptide going into the directory, and another product of Essex peptide more directly did not enter the directory. Glp-1 drugs listed early attention, but the performance is acceptable in the domestic market, in 2016 samples of hospital lalu peptide sales increased to nearly 30 million yuan, but its share of diabetes is minimal. Injections of drugs and relatively high prices discourage clinical use, so cutting prices and entering health care is an opportunity for the glp-1 drug.
Quintiapine, paroxetine
A: yes, please
Spiritual quetiapine flat zyban and paroxetine enteric zyban sustained-release dosage form is the new directory into the negotiations, but the two negotiations are feeling chicken ribs. Qutiapine is currently in the lower ranks of antipsychotic medications, and the market has barely opened up after the release of the paroxetine tablet. Two varieties are unlikely to have a significant impact on the market even if the price of a price is dropped.
summarize
The direction of future negotiations should be developed
The price negotiation varieties screening can greatly release the needs of the industry, for the most part should be going into the directory of variety in the negotiations directory, at the same time the future drug negotiations will gradually normalized, this is definitely a good for pharmaceutical companies, especially for innovative drugs in the future will shorten time-to-market to enter the health care.
Refer to the first and second national price negotiations to screen the direction of the varieties, we expect the future negotiations varieties screening in based on the special patent medicine or exclusive varieties and the price is higher under the premise of patients burden is bigger, may have the following features:
In the context of the first two deaths of Chinese people in tumors and heart blood vessels, the variety will continue to focus on new treatments for two types of disease. In the field of tumor, monoclonal antibody and the hot spot in the TKI drugs still, but some of the new drug for mechanism (including the current hot drugs and PD - 1 cancer vaccine) will become the new focus. In the cerebrovascular field, the treatment of basic diseases such as hypertension and hyperlipids is more mature, so thrombotic diseases will be the main focus. In addition, in the case of heart cerebrovascular intervention, can some instruments and materials be included in the negotiation catalogue?
Whether the new medical insurance directory or negotiations varieties can see directory, orphan drug will become the focus in the future, in view of the high price of orphan drug widely, through negotiations and sharply lower prices for orphan drug into health care is a good choice. The number of orphan drugs previously included is limited, and as the negotiations normalise, more orphan drugs are expected to be negotiated into health care in the future.
In addition to the rare group of patients, screening for health care and negotiation will also focus on certain groups of people. In under the background of aging degenerative disease common price is too high, the future including diseases such as alzheimer's, Parkinson's drug use is expected to be negotiated will be more and more new drugs included. Medication for children will also be a major concern, especially in developing pediatric specific dosage forms. In addition, for some diseases treatment cost is quite high or low quality of life in patients with the disease, such as patients with organ transplantation, HIV/AIDS, liver and kidney function failure, some of the high cost of entering medicare varieties could also become a target for negotiation.
Medicare catalog for vaccine were not at the moment, but we all know that vaccination costs significantly below often have not caused by implementation of immune health spending, for some of the price is relatively high, 2 kinds of vaccines, such as HPV vaccine, pei son 13, etc., can enter the health care and encourage clinical application through negotiations? Some developed regions in the country have successfully tried this. At the national level, price negotiations allow the vaccine to lower prices and cover some of the cost of health care, which will help the use of these vaccines.
The price negotiations included three innovative preparations. In medical insurance directory only commonly included in the formulation, often through negotiations into medical insurance directory to the new preparations of an opportunity for the development enterprise, especially the development of the high cost of microsphere, liposomes and nanoparticles preparation, etc. Varieties for traditional Chinese medicines, the negotiations varieties mainly involves some new elements clearer or single Chinese medicine injection, at the security problems of TCM injections, the early development of traditional Chinese medicine injection problem, through negotiations let new TCM injections into health care can also help out early TCM injections to achieve upgrading.
|
